Review



bioactive compounds  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    TargetMol bioactive compounds
    Bioactive Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/Bioactive+Compounds+Library+Max/pm42826556-88-4-6
    Average 94 stars, based on 26 article reviews
    bioactive compounds - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Drug discovery:

    Article Title: Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation.
    Article Snippet: Plasmids were transfected into hEECs and Ishikawa cells using Lipofectamine 2000 (Invitrogen). .. A compound library containing 996 bioactive compounds was provided by TargetMol. ..

    Article Title: Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.
    Article Snippet: .. .21 Small Molecule Virtual Screening o identify small-molecule inhibitors that potentially disrupt he interaction between p-GSK3 β-Y216 and the S977 region of NMT1, virtual screening was performed using a bioactive dvanced Science, 2026 compound library from the TargetMol database ( https://www. .. targetmol.cn ), comprising 17,760 known bioactive compounds.

    Activity Assay:

    Article Title: A rapid sporozoite viability assay identifies leads and targetable enzymatic activities against the zoonotic Cryptosporidium parvum.
    Article Snippet: The mixtures were incubated at 25 ◦C for 3 h, and fluorescence signals were measured using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments) with excitation at 560 nm and emission at 590 nm. .. A library of 5000 bioactive compounds (Topscience, Shanghai, China) was screened for activity against C. parvum sporozoite viability using the luminescence ATP assay. ..

    Article Title: A rapid sporozoite viability assay identifies anti- Cryptosporidium parvum leads and targetable enzymatic activities in the invasive stage
    Article Snippet: The mixtures were incubated at 25 °C for 3 h, and fluorescence signals were measured using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments) with excitation at 560 nm and emission at 590 nm. .. A library of 5,000 bioactive compounds (Topscience, Shanghai, China) was screened for activity against C. parvum sporozoite viability using the luminescence ATP assay. ..

    ATP Assay:

    Article Title: A rapid sporozoite viability assay identifies leads and targetable enzymatic activities against the zoonotic Cryptosporidium parvum.
    Article Snippet: The mixtures were incubated at 25 ◦C for 3 h, and fluorescence signals were measured using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments) with excitation at 560 nm and emission at 590 nm. .. A library of 5000 bioactive compounds (Topscience, Shanghai, China) was screened for activity against C. parvum sporozoite viability using the luminescence ATP assay. ..

    Article Title: A rapid sporozoite viability assay identifies anti- Cryptosporidium parvum leads and targetable enzymatic activities in the invasive stage
    Article Snippet: The mixtures were incubated at 25 °C for 3 h, and fluorescence signals were measured using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments) with excitation at 560 nm and emission at 590 nm. .. A library of 5,000 bioactive compounds (Topscience, Shanghai, China) was screened for activity against C. parvum sporozoite viability using the luminescence ATP assay. ..

    Screening:

    Article Title: Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.
    Article Snippet: .. .21 Small Molecule Virtual Screening o identify small-molecule inhibitors that potentially disrupt he interaction between p-GSK3 β-Y216 and the S977 region of NMT1, virtual screening was performed using a bioactive dvanced Science, 2026 compound library from the TargetMol database ( https://www. .. targetmol.cn ), comprising 17,760 known bioactive compounds.

    other:

    Article Title: Discovery of 6l with a New Skeleton of 6-Oxo- N -(4-(Quinolin-4-yloxy)phenyl)-1,6-dihydropyridine-3-carboxamide as a Dual-Action Inhibitor against JNK2 and the MKK7-JNK2 Protein-Protein Interaction for Acute Lung Injury.
    Article Snippet: The development of anti-inflammatory drugs is a research focus.. Acute lung injury (ALI) is a life-threatening inflammatory syndrome that currently lacks effective pharmacotherapies.. Here, we report a potential therapy for ALI by targeting c-Jun N-terminal kinase 2 (JNK2), a key regulator of MAPK pathway-driven inflammatory responses.

    Article Title: From virtual screening to reality: Identifying potent PI3Kγ inhibitors for inflammation treatment by harnessing machine learning and biological validation.
    Article Snippet: Research increasingly shows that excessive activation of phosphoinositide 3-kinase gamma (PI3Kγ) is linked to numerous inflammatory factors, highlighting its potential as a drug target for inflammatory disorder treatment.. Nonetheless, few inhibitors have advanced to clinical trials for inflammation treatment.. One of the major reasons for this is the extreme difficulty in developing selective PI3Kγ inhibitors due to the high homology among kinase structures.



    Similar Products

    95
    TargetMol molecule library
    Molecule Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/Bioactive+Compound+Library/10__1186_slash_s13048___026___02230___7-82-3-11
    Average 95 stars, based on 1 article reviews
    molecule library - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    TargetMol small molecule compound library
    Small Molecule Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/Target-Focused+Phenotypic+Screening+Library/pmc13538362-350-5-9
    Average 94 stars, based on 1 article reviews
    small molecule compound library - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    MedChemExpress small molecule compounds sb290157
    A Chemical structures of small molecule ligands of C3aR, <t>SB290157</t> and JR14a, drawn using ChemDraw software. B SB290157/JR14a-induced G-protein-coupling measured using NanoBiT-based G-protein dissociation and GloSensor-based cAMP assays upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized with respect to the response at the lowest ligand concentration treated as 100% (mean ± SEM; n = 3 independent experiments). C SB290157/JR14a-induced βarr1/2 recruitment measured using a NanoBiT-based assay upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized to the response at the lowest ligand concentration, which was set to 1 (mean ± SEM; n = 3 independent experiments). Comparison of Emax and EC 50 values of the corresponding data are presented in Supplementary Table . Source data are provided as a file.
    Small Molecule Compounds Sb290157, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/SB290157/pmc13635228-224-0-8
    Average 95 stars, based on 1 article reviews
    small molecule compounds sb290157 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    TargetMol selleck small molecule compound libraries
    Cobicistat was identified as a novel MEST inhibitor. (A) Eight binding pockets of MEST were identified using the SiteFinder module of MOE software. (B) Virtual docking screening of MEST inhibitor from a library. (C) A preliminary screening of 36 compounds was performed by SPR. (D) Binding affinity of the cobicistat to human MEST assessed by SPR. (E) Molecular structure of cobicistat small molecule. (F) Computational model and the interaction of cobicistat with MEST complex. (G) The interacting amino acids and hydrogen bonds between the complexes.
    Selleck Small Molecule Compound Libraries, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/Target-Focused+Phenotypic+Screening+Library/pmc13481203-156-13-11
    Average 94 stars, based on 1 article reviews
    selleck small molecule compound libraries - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    MedChemExpress molecule compounds tepp 46
    Dose-responsive target-responsive accessibility profiling (TRAP) <t>identifies</t> <t>TEPP-46</t> targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.
    Molecule Compounds Tepp 46, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/TEPP-46/pmc13485670-38-1-11
    Average 96 stars, based on 1 article reviews
    molecule compounds tepp 46 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    MedChemExpress molecule compounds
    Dose-responsive target-responsive accessibility profiling (TRAP) <t>identifies</t> <t>TEPP-46</t> targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.
    Molecule Compounds, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/LY294002/pmc13270114-297-1-6
    Average 99 stars, based on 1 article reviews
    molecule compounds - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    86
    Arcus Biosciences dgkα small molecule inhibitor compound α i
    Dose-responsive target-responsive accessibility profiling (TRAP) <t>identifies</t> <t>TEPP-46</t> targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.
    Dgkα Small Molecule Inhibitor Compound α I, supplied by Arcus Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/cd73+inhibitor+molecule+small/pm42068678-70-0-9
    Average 86 stars, based on 1 article reviews
    dgkα small molecule inhibitor compound α i - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Arcus Biosciences dgkζ small molecule inhibitor compounds
    Dose-responsive target-responsive accessibility profiling (TRAP) <t>identifies</t> <t>TEPP-46</t> targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.
    Dgkζ Small Molecule Inhibitor Compounds, supplied by Arcus Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/cd73+inhibitor+molecule+small/pm42068678-71-1-12
    Average 86 stars, based on 1 article reviews
    dgkζ small molecule inhibitor compounds - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    94
    Selleck Chemicals small molecule library
    Dose-responsive target-responsive accessibility profiling (TRAP) <t>identifies</t> <t>TEPP-46</t> targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.
    Small Molecule Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/small+molecule+compounds/Bioactive+Compound+Library-%E2%85%A1/pmc13006433-355-31-35
    Average 94 stars, based on 1 article reviews
    small molecule library - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    A Chemical structures of small molecule ligands of C3aR, SB290157 and JR14a, drawn using ChemDraw software. B SB290157/JR14a-induced G-protein-coupling measured using NanoBiT-based G-protein dissociation and GloSensor-based cAMP assays upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized with respect to the response at the lowest ligand concentration treated as 100% (mean ± SEM; n = 3 independent experiments). C SB290157/JR14a-induced βarr1/2 recruitment measured using a NanoBiT-based assay upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized to the response at the lowest ligand concentration, which was set to 1 (mean ± SEM; n = 3 independent experiments). Comparison of Emax and EC 50 values of the corresponding data are presented in Supplementary Table . Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Molecular basis of diverse ligand recognition and species-specific pharmacology at the complement anaphylatoxin receptor C3aR

    doi: 10.1038/s41467-026-76518-z

    Figure Lengend Snippet: A Chemical structures of small molecule ligands of C3aR, SB290157 and JR14a, drawn using ChemDraw software. B SB290157/JR14a-induced G-protein-coupling measured using NanoBiT-based G-protein dissociation and GloSensor-based cAMP assays upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized with respect to the response at the lowest ligand concentration treated as 100% (mean ± SEM; n = 3 independent experiments). C SB290157/JR14a-induced βarr1/2 recruitment measured using a NanoBiT-based assay upon stimulation of HEK-293 cells expressing the indicated receptors. Data was normalized to the response at the lowest ligand concentration, which was set to 1 (mean ± SEM; n = 3 independent experiments). Comparison of Emax and EC 50 values of the corresponding data are presented in Supplementary Table . Source data are provided as a file.

    Article Snippet: Small-molecule compounds SB290157 and JR14a were obtained from MedChem Express (Cat. No: HY-101502A for SB290157; Cat. No: HY-138161 for JR14a).

    Techniques: Software, Expressing, Concentration Assay, Comparison

    A–K Structural comparison of the indicated structures, highlighting the key differences in the overall positioning of various ligands in the orthosteric pocket of the human and mouse C3aR. PDB: 8I9L for hC3a-hC3aR, 9KZK for mC3a-mC3aR, 9KV8 for hTLQP-21-mC3aR, 9KV6 for mTLQP-21-mC3aR, 8I95 for EP54-hC3aR, 9UMJ for EP54-mC3aR, 9KUT for JR14a-hC3aR, 9L0H for JR14a-mC3aR and 9KVP for SB290157-hC3aR complex.

    Journal: Nature Communications

    Article Title: Molecular basis of diverse ligand recognition and species-specific pharmacology at the complement anaphylatoxin receptor C3aR

    doi: 10.1038/s41467-026-76518-z

    Figure Lengend Snippet: A–K Structural comparison of the indicated structures, highlighting the key differences in the overall positioning of various ligands in the orthosteric pocket of the human and mouse C3aR. PDB: 8I9L for hC3a-hC3aR, 9KZK for mC3a-mC3aR, 9KV8 for hTLQP-21-mC3aR, 9KV6 for mTLQP-21-mC3aR, 8I95 for EP54-hC3aR, 9UMJ for EP54-mC3aR, 9KUT for JR14a-hC3aR, 9L0H for JR14a-mC3aR and 9KVP for SB290157-hC3aR complex.

    Article Snippet: Small-molecule compounds SB290157 and JR14a were obtained from MedChem Express (Cat. No: HY-101502A for SB290157; Cat. No: HY-138161 for JR14a).

    Techniques: Comparison

    Selected interactions of the indicated ligands in the orthosteric pocket of the human and mouse C3aR, highlighting the conserved interactions with those of C3a. PDB: 8I9L for hC3a-hC3aR, 9KZK for mC3a-mC3aR, 9KV8 for hTLQP-21-mC3aR, 9KV6 for mTLQP-21-mC3aR, 8I95 for EP54-hC3aR, 9UMJ for EP54-mC3aR, 9KUT for JR14a-hC3aR, 9L0H for JR14a-mC3aR and 9KVP for SB290157-hC3aR complex.

    Journal: Nature Communications

    Article Title: Molecular basis of diverse ligand recognition and species-specific pharmacology at the complement anaphylatoxin receptor C3aR

    doi: 10.1038/s41467-026-76518-z

    Figure Lengend Snippet: Selected interactions of the indicated ligands in the orthosteric pocket of the human and mouse C3aR, highlighting the conserved interactions with those of C3a. PDB: 8I9L for hC3a-hC3aR, 9KZK for mC3a-mC3aR, 9KV8 for hTLQP-21-mC3aR, 9KV6 for mTLQP-21-mC3aR, 8I95 for EP54-hC3aR, 9UMJ for EP54-mC3aR, 9KUT for JR14a-hC3aR, 9L0H for JR14a-mC3aR and 9KVP for SB290157-hC3aR complex.

    Article Snippet: Small-molecule compounds SB290157 and JR14a were obtained from MedChem Express (Cat. No: HY-101502A for SB290157; Cat. No: HY-138161 for JR14a).

    Techniques:

    A Structural comparison of SB290157 and JR14a binding pose to human and mouse C3aR. B Structural comparison of SB290157- and JR14a-bound C3aR structure with the inactive C5aR1 reveals activation-dependent structural changes, including the outwards movement of TM6, TM7 and Helix8. C , D SB290157/JR14a-induced cAMP response and βarr1 recruitment measured using the GloSensor assay and NanoBiT-based assay, respectively, upon stimulation of HEK-293 cells expressing the indicated receptor mutants. Data were normalized with the response for the wild-type treated as 100% (mean; n = 3 independent experiments). Comparison of ligand pharmacology of the above data are presented in Supplementary Tables . Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Molecular basis of diverse ligand recognition and species-specific pharmacology at the complement anaphylatoxin receptor C3aR

    doi: 10.1038/s41467-026-76518-z

    Figure Lengend Snippet: A Structural comparison of SB290157 and JR14a binding pose to human and mouse C3aR. B Structural comparison of SB290157- and JR14a-bound C3aR structure with the inactive C5aR1 reveals activation-dependent structural changes, including the outwards movement of TM6, TM7 and Helix8. C , D SB290157/JR14a-induced cAMP response and βarr1 recruitment measured using the GloSensor assay and NanoBiT-based assay, respectively, upon stimulation of HEK-293 cells expressing the indicated receptor mutants. Data were normalized with the response for the wild-type treated as 100% (mean; n = 3 independent experiments). Comparison of ligand pharmacology of the above data are presented in Supplementary Tables . Source data are provided as a file.

    Article Snippet: Small-molecule compounds SB290157 and JR14a were obtained from MedChem Express (Cat. No: HY-101502A for SB290157; Cat. No: HY-138161 for JR14a).

    Techniques: Comparison, Binding Assay, Activation Assay, Expressing

    Cobicistat was identified as a novel MEST inhibitor. (A) Eight binding pockets of MEST were identified using the SiteFinder module of MOE software. (B) Virtual docking screening of MEST inhibitor from a library. (C) A preliminary screening of 36 compounds was performed by SPR. (D) Binding affinity of the cobicistat to human MEST assessed by SPR. (E) Molecular structure of cobicistat small molecule. (F) Computational model and the interaction of cobicistat with MEST complex. (G) The interacting amino acids and hydrogen bonds between the complexes.

    Journal: Frontiers in Oncology

    Article Title: Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling

    doi: 10.3389/fonc.2026.1901635

    Figure Lengend Snippet: Cobicistat was identified as a novel MEST inhibitor. (A) Eight binding pockets of MEST were identified using the SiteFinder module of MOE software. (B) Virtual docking screening of MEST inhibitor from a library. (C) A preliminary screening of 36 compounds was performed by SPR. (D) Binding affinity of the cobicistat to human MEST assessed by SPR. (E) Molecular structure of cobicistat small molecule. (F) Computational model and the interaction of cobicistat with MEST complex. (G) The interacting amino acids and hydrogen bonds between the complexes.

    Article Snippet: Here, we identified a candidate MEST-inhibitory compound, cobicistat, by screening the TargetMol and Selleck small-molecule compound libraries based on its catalytic site, ASN163.

    Techniques: Binding Assay, Software, Docking Assay, Screening

    Dose-responsive target-responsive accessibility profiling (TRAP) identifies TEPP-46 targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.

    Journal: Journal of Pharmaceutical Analysis

    Article Title: DT-TRAP enables accurate target recognition via simplified dosing and low-temperature incubation

    doi: 10.1016/j.jpha.2026.101605

    Figure Lengend Snippet: Dose-responsive target-responsive accessibility profiling (TRAP) identifies TEPP-46 targets in complex proteomes. (A) Volcano plots showing lysine accessibility changes in HeLa cell lysates. Each treatment group contained 100 μg of HeLa lysate and was treated with TEPP-46 at multiple concentrations (1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 μM, 5 μM, and 10 μM), followed by ligand incubation for 1 h and TRAP labeling for 30 min, both performed at 25 °C. Thresholds were defined as TRAP ratio <0.5 or >2 with statistical significance assessed by one-way analysis of variance (ANOVA); ∗∗∗P < 0.001. (B) Dose-responsive accessibility changes at lysine residues K305/K311 of pyruvate kinase M2 (PKM2) upon TEPP-46 treatment, fitted using a four-parameter logistic (4 PL) model ( R 2 = 0.9951; n = 3 independent biological replicates). (C) Quantitative TRAP analysis of lysine-containing peptides within PKM2. Blue indicates TRAP peptides exhibiting the strongest accessibility changes, while cyan denotes peptides showing weaker or inconsistent changes ( n = 3 independent biological replicates). (D) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) bound near the K305/K311 region. The TRAP-identified peptide segment exhibiting altered accessibility (K305/K311) is highlighted in blue, whereas non-responsive peptides are shown in cyan. PDB: protein data bank.

    Article Snippet: The small-molecule compounds TEPP-46, geldanamycin, staurosporine, and aspirin were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

    Techniques: Incubation, Labeling

    Target identification of TEPP-46 using two- and three-dose target-responsive accessibility profiling (TRAP) analyses. (A) Quadrant plot showing proteins with consistent lysine accessibility changes in HeLa cell lysates. Each group contained 100 μg of HeLa cell lysate and was treated with TEPP-46 at 1 and 5 μM, followed by ligand incubation for 1 h at 25 °C and TRAP labeling for 30 min at the same temperature ( n = 3 independent biological replicates). Proteins with TRAP ratios (TEPP-46/control >2 or < 0.5) and statistical significance assessed by one-way analysis of variance (ANOVA; ∗∗∗ P < 0.001) were designated as potential targets. Accessibility decreases and increases are highlighted in blue and red, respectively. Each protein is represented by the peptide with the highest TRAP score. (B) Three-dimensional scatter plot showing shared targets across three doses of TEPP-46 (1, 5, and 10 μM). Drug incubation and TRAP labeling conditions were identical to those described in (A). Pyruvate kinase M2 (PKM2) was identified as the only consistent target (red) under statistical thresholds (TRAP ratio >2 or < 0.5; one-way ANOVA; ∗∗∗ P < 0.001). (C) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) binding and corresponding lysine accessibility changes. The TRAP-identified peptide containing residues K305/K311 is highlighted in blue, whereas non-responsive peptides are shown in cyan, statistical significance assessed by one-way ANOVA (∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001). PDB: protein data bank.

    Journal: Journal of Pharmaceutical Analysis

    Article Title: DT-TRAP enables accurate target recognition via simplified dosing and low-temperature incubation

    doi: 10.1016/j.jpha.2026.101605

    Figure Lengend Snippet: Target identification of TEPP-46 using two- and three-dose target-responsive accessibility profiling (TRAP) analyses. (A) Quadrant plot showing proteins with consistent lysine accessibility changes in HeLa cell lysates. Each group contained 100 μg of HeLa cell lysate and was treated with TEPP-46 at 1 and 5 μM, followed by ligand incubation for 1 h at 25 °C and TRAP labeling for 30 min at the same temperature ( n = 3 independent biological replicates). Proteins with TRAP ratios (TEPP-46/control >2 or < 0.5) and statistical significance assessed by one-way analysis of variance (ANOVA; ∗∗∗ P < 0.001) were designated as potential targets. Accessibility decreases and increases are highlighted in blue and red, respectively. Each protein is represented by the peptide with the highest TRAP score. (B) Three-dimensional scatter plot showing shared targets across three doses of TEPP-46 (1, 5, and 10 μM). Drug incubation and TRAP labeling conditions were identical to those described in (A). Pyruvate kinase M2 (PKM2) was identified as the only consistent target (red) under statistical thresholds (TRAP ratio >2 or < 0.5; one-way ANOVA; ∗∗∗ P < 0.001). (C) Crystal structure of PKM2 (PDB: 3U2Z ) showing TEPP-46 (yellow) binding and corresponding lysine accessibility changes. The TRAP-identified peptide containing residues K305/K311 is highlighted in blue, whereas non-responsive peptides are shown in cyan, statistical significance assessed by one-way ANOVA (∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001). PDB: protein data bank.

    Article Snippet: The small-molecule compounds TEPP-46, geldanamycin, staurosporine, and aspirin were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

    Techniques: Drug discovery, Incubation, Labeling, Control, Binding Assay